Table 4.
Evaluation of diagnostic value of autoantibodies to different combinations of tumor‐associated antigens (TAAs)
| TAA panel | Positive (%) | Sensitivity (%) | Specificity (%) | YI | ++LR | −LR | PPV (%) | NPV (%) | Accuracy (%) | |
|---|---|---|---|---|---|---|---|---|---|---|
| OC (n = 164) | NHS (n = 164) | |||||||||
| p53 | 57 (34.76) | 8 (4.88) | 34.76 | 95.12 | 0.2988 | 7.13 | 0.69 | 87.69 | 59.32 | 64.94 |
| p53 or GNAS | 74 (45.12) | 15 (9.15) | 45.12 | 90.85 | 0.3598 | 4.93 | 0.60 | 83.15 | 62.34 | 67.99 |
| p53 or GNAS or NPM1 | 84 (51.22) | 23 (14.02) | 51.22 | 85.98 | 0.3720 | 3.65 | 0.57 | 78.50 | 63.80 | 68.60 |
| p53 or GNAS or NPM1 or KRAS | 85 (51.83) | 27 (16.46) | 51.83 | 83.54 | 0.3537 | 3.15 | 0.58 | 75.89 | 63.43 | 67.68 |
Abbreviations: +LR, positive likelihood ratio; −LR, negative likelihood ratio; NHS, normal health sera; NPV, negative predictive value; OC, ovarian cancer; PPV, positive predictive value; YI, Youden’s index.